Adaptive Biotechnologies Corp is trading 6.7% higher at $19.99 in pre-market, extending a rally driven by positive company developments.
- The surge follows the company showcasing new positive results for its clonoSEQ testing platform at the EHA 2026 Congress.
- Momentum is also attributed to management's recently upgraded 2026 revenue outlook, which has fueled investor optimism.
- The stock is extending strong gains from the previous session, where it closed up over 9.7%.